文献速递胰腺与胆道疾病

粪便弹性蛋白酶-1检测外分泌胰腺功能不全的诊断性能:系统综述与Meta分析

Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-01-31

该系统综述与Meta分析纳入14项研究共428例外分泌胰腺功能不全(EPI)患者和673例无EPI对照,评估粪便弹性蛋白酶-1诊断EPI的准确性。与促胰液素刺激试验相比,合并敏感度为0.77(95%CI 0.58-0.89)、特异度为0.88(95%CI 0.78-0.93);与定量粪便脂肪检测相比,合并敏感度为0.96(95%CI 0.79-0.99)、特异度为0.88(95%CI 0.59-0.97)。在EPI低验前概率(5%)患者中,假阴性率为1.1%、假阳性率为11%,正常水平(>200 mcg/g)可排除EPI,但异常水平(<200 mcg/g)假阳性率高。

要点

  • 粪便弹性蛋白酶-1正常(>200 mcg/g)可在低验前概率(5%)患者中排除EPI,假阴性率1.1%。
  • 粪便弹性蛋白酶-1异常(<200 mcg/g)在低验前概率患者中假阳性率高达11%。
  • 在高验前概率(40%)患者中,约10%的EPI患者会被漏诊(假阴性)。

核心结论

  • 粪便弹性蛋白酶-1正常水平(>200 mcg/g)可在EPI低概率患者(如腹泻型肠易激综合征)中排除EPI。
  • 在EPI低概率患者中,粪便弹性蛋白酶-1异常水平(<200 mcg/g)具有高假阳性率。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase及参考文献列表至2016年11月,纳入14项研究,共428例EPI患者和673例无EPI对照。

主要发现

  • 与促胰液素刺激试验相比,粪便弹性蛋白酶-1检测EPI的合并敏感度为0.77(95%CI 0.58-0.89),特异度为0.88(95%CI 0.78-0.93)。
  • 与定量粪便脂肪检测相比(6项研究,345例EPI患者和312例对照),合并敏感度为0.96(95%CI 0.79-0.99),特异度为0.88(95%CI 0.59-0.97)。
  • 在EPI低验前概率(5%)患者中,假阴性率为1.1%,假阳性率为11%。
  • 在EPI高验前概率(40%)患者中,约10%的EPI患者被漏诊(假阴性)。

关键数值与推荐

  • 粪便弹性蛋白酶-1正常水平定义为>200 mcg/g,异常水平定义为<200 mcg/g。

临床怎么用

  • 在EPI低概率患者中,粪便弹性蛋白酶-1正常(>200 mcg/g)可用于排除EPI。
  • 在EPI低概率患者中,粪便弹性蛋白酶-1异常(<200 mcg/g)假阳性率高,不适用于检出EPI。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tests to quantify fecal levels of chymotrypsin like elastase family member 3 (CELA3 or elastase-1) in feces are widely used to identify patients with exocrine pancreatic insufficiency (EPI). However, the diagnostic accuracy of this test, an ELISA, is not clear. We performed a systematic review and meta-analysis to determine the accuracy of measurement of fecal elastase-1 in detection of EPI. METHODS: We searched PubMed, Embase, and reference lists for articles through November 2016 describing studies that compared fecal level of elastase-1 with results from a reference standard, direct method (secretin stimulation test), or indirect method (measurement of fecal fat) for detection of EPI. Sensitivity and specificity values were pooled statistically using bivariate diagnostic meta-analysis. RESULTS: We included total of 428 cases of EPI and 673 individuals without EPI (controls), from 14 studies, in the meta-analysis. The assay for elastase-1, compared to secretin stimulation test, identified patients with pancreatic insufficiency with a pooled sensitivity value of 0.77 (95% CI, 0.58-0.89) and specificity value of 0.88 (95% CI, 0.78-0.93). In an analysis of 345 cases of EPI and 312 controls, from 6 studies, the fecal elastase-1 assay identified patients with EPI with a pooled sensitivity value of 0.96 (95% CI, 0.79-0.99) and specificity value of 0.88 (95% CI, 0.59-0.97), compared to quantitative fecal fat estimation. In patients with low pre-test probability of EPI (5%), the fecal elastase-1 assay would have a false-negative rate of 1.1% and a false-positive rate of 11%, indicating a high yield in ruling out EPI but not in detection of EPI. In contrast, in patients with high pre-test probability of EPI (40%), approximately 10% of patients with EPI would be missed (false negatives). CONCLUSIONS: In a systematic review and meta-analysis of studies that compared fecal level of elastase-1 for detection of EPI, we found that normal level of elastase-1 (above 200 mcg/g) can rule out EPI in patients with a low probability of this disorder (such as those with irritable bowel syndrome with diarrhea). However, in these patients, an abnormal level of elastase-1 (below 200 mcg/g) has a high false-positive rate.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vanga RR, Tansel A, Sidiq S, et al. Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID: 29374614. doi:10.1016/j.cgh.2018.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。